ProCE Banner Activity

Progress in the Development of Antibody–Drug Conjugates Targeting TROP-2 for Advanced NSCLC

Clinical Thought

Read this commentary for an expert review of what we know so far about the TROP-2–targeting ADCs datopotamab deruxtecan and sacituzumab govitecan in the management of non-small-lung cancer, including key differentiating toxicities, early-phase results, and ongoing trials continuing to evaluate these promising treatments

Released: July 19, 2023

Share

Faculty

Yasushi Goto

Yasushi Goto, MD, PhD

Assistant Chief 
Department of Thoracic Oncology 
National Cancer Center Hospital Japan
Tokyo, Japan 

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Disclosure

Primary Author

Yasushi Goto, MD, PhD

Assistant Chief 
Department of Thoracic Oncology 
National Cancer Center Hospital Japan
Tokyo, Japan 

Yasushi Goto, MD, PhD: consultant/advisor/speaker: Boehringer Ingelheim, Bristol Myers Squibb, Chugai, Lilly, Merck, MSD, Novartis, Ono, Pfizer, Thermo Fisher; research grants (paid to institution): AbbVie, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Kyorin, Novartis, Ono, Pfizer, Preferred Network; research grants (paid to clinical trial group): AZK, Pfizer; advisory board: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Chugai, Daiichi Sankyo, Guardant Health, Illumina, Lilly, MSD, Novartis, Ono, Pfizer, Taiho.